CN118221610A - 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 - Google Patents
一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 Download PDFInfo
- Publication number
- CN118221610A CN118221610A CN202410660509.2A CN202410660509A CN118221610A CN 118221610 A CN118221610 A CN 118221610A CN 202410660509 A CN202410660509 A CN 202410660509A CN 118221610 A CN118221610 A CN 118221610A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- methoxy
- hydroxy
- sulfamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Phenylthiazole amine Chemical class 0.000 title claims abstract description 127
- 239000003112 inhibitor Substances 0.000 title claims abstract description 36
- 101000730433 Homo sapiens Phosphatidylinositol 4-kinase beta Proteins 0.000 title claims abstract description 35
- 102100032619 Phosphatidylinositol 4-kinase beta Human genes 0.000 title claims abstract description 35
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 32
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 33
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 19
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 16
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- WFWKNGZODAOLEO-UHFFFAOYSA-N 1-(4-Methoxyphenyl)-2-propanone Chemical compound COC1=CC=C(CC(C)=O)C=C1 WFWKNGZODAOLEO-UHFFFAOYSA-N 0.000 claims description 10
- 230000009977 dual effect Effects 0.000 claims description 10
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 229940124530 sulfonamide Drugs 0.000 claims description 10
- 150000003456 sulfonamides Chemical class 0.000 claims description 10
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims description 9
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 238000005893 bromination reaction Methods 0.000 claims description 6
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 5
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 238000005595 Hinsberg synthesis reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 150000001263 acyl chlorides Chemical class 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- CNRMXICSYWVJRD-UHFFFAOYSA-N methyl 5-formyl-2-methoxybenzoate Chemical compound COC(=O)C1=CC(C=O)=CC=C1OC CNRMXICSYWVJRD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 108091007960 PI3Ks Proteins 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 abstract description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract description 2
- 239000013067 intermediate product Substances 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 133
- 239000000243 solution Substances 0.000 description 42
- 239000007787 solid Substances 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 33
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 11
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000003905 phosphatidylinositols Chemical class 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- WPGPRLVPWACBHW-UHFFFAOYSA-N (4-methoxy-4-oxobutyl)azanium;chloride Chemical compound Cl.COC(=O)CCCN WPGPRLVPWACBHW-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 7
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- DPLJNTWBXCKJOL-UHFFFAOYSA-N 3-bromo-4,5-diethoxybenzonitrile Chemical compound CCOC1=CC(C#N)=CC(Br)=C1OCC DPLJNTWBXCKJOL-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- FAKIZCQRTPAOSH-UHFFFAOYSA-N methyl 5-aminopentanoate;hydrochloride Chemical compound Cl.COC(=O)CCCCN FAKIZCQRTPAOSH-UHFFFAOYSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 5
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 4
- 101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- JCEWAIRJQKPKBH-UHFFFAOYSA-N 2-methoxy-5-(2-oxopropyl)benzenesulfonyl chloride Chemical compound COC1=CC=C(CC(C)=O)C=C1S(Cl)(=O)=O JCEWAIRJQKPKBH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- YSLDOTFAFZJPOC-UHFFFAOYSA-N hydron;methyl 6-aminohexanoate;chloride Chemical compound Cl.COC(=O)CCCCCN YSLDOTFAFZJPOC-UHFFFAOYSA-N 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- JFVNFXCESCXMBC-UHFFFAOYSA-N n-[5-[4-chloro-3-(2-hydroxyethylsulfamoyl)phenyl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound S1C(=N/C(=O)C)\NC(C)=C1C1=CC=C(Cl)C(S(=O)(=O)NCCO)=C1 JFVNFXCESCXMBC-UHFFFAOYSA-N 0.000 description 3
- MYFXFDSWVICTMJ-UHFFFAOYSA-N n-carbamothioyl-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC(S)=N MYFXFDSWVICTMJ-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000237 vorinostat Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CHMAEAFFKRYPQT-UHFFFAOYSA-N (7-methoxy-7-oxoheptyl)azanium;chloride Chemical compound Cl.COC(=O)CCCCCCN CHMAEAFFKRYPQT-UHFFFAOYSA-N 0.000 description 2
- MQQJFLHZXQRKKJ-UHFFFAOYSA-N 2-methoxy-5-(2-oxopropyl)benzenesulfonamide Chemical compound COC1=CC=C(CC(C)=O)C=C1S(N)(=O)=O MQQJFLHZXQRKKJ-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- 102100030829 Armadillo-like helical domain-containing protein 3 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000792905 Homo sapiens Armadillo-like helical domain-containing protein 3 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009061 membrane transport Effects 0.000 description 2
- MNTBBHUAKVFLDX-UHFFFAOYSA-N methyl 2-methoxy-5-(2-oxopropyl)benzoate Chemical compound COC(=O)C1=CC(CC(C)=O)=CC=C1OC MNTBBHUAKVFLDX-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 description 1
- 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100033415 Golgi resident protein GCP60 Human genes 0.000 description 1
- 108091005772 HDAC11 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000926911 Homo sapiens Golgi resident protein GCP60 Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- UJVUMTUBMCYKBK-BNOPZSDTSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,3,5,6-tetrahydroxy-4-phosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](O)C(OP(O)(O)=O)[C@H](O)[C@H]1O UJVUMTUBMCYKBK-BNOPZSDTSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical group [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- VDEUYMSGMPQMIK-UHFFFAOYSA-N benzhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1 VDEUYMSGMPQMIK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- RZWZDIVNLQZHGB-UHFFFAOYSA-N chloroform;methylsulfinylmethane Chemical compound CS(C)=O.ClC(Cl)Cl RZWZDIVNLQZHGB-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XPGRZDJXVKFLHQ-UHFFFAOYSA-N hydron;methyl 3-aminopropanoate;chloride Chemical compound Cl.COC(=O)CCN XPGRZDJXVKFLHQ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- YKKLMHVRCUIUIT-UHFFFAOYSA-N methyl 4-(2-aminoethoxy)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(OCCN)C=C1 YKKLMHVRCUIUIT-UHFFFAOYSA-N 0.000 description 1
- KVQGGLZHHFGHPU-UHFFFAOYSA-N methyl 4-aminobutanoate Chemical compound COC(=O)CCCN KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108091005706 peripheral membrane proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229950001415 tucidinostat Drugs 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009265 virologic response Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用，属于医药技术领域。本发明提供一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂，为通式I所示的取代苯基噻唑胺类化合物，或其立体异构体、水合物或药学上可接受的盐。本发明有益效果：（1）具有有效抑制PI4KIIIβ的PI3K/Akt/mTOR信号通路的特点，具有高效优异的PI4KIIIβ/HDAC双酶抑制活性；（2）成本低、疗效佳、毒性小，且在合成过程中的中间产物收率高，降低了资源浪费，进而有利于降低成本；（3）有较高抗丙型肝炎病毒的活性，使用剂量小。
Description
技术领域
本发明涉及一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用，属于医药技术领域。
背景技术
磷脂酰肌醇4-激酶（PI4Ks）的高表达与多种疾病密切相关，包括病毒感染、癌症、疟疾以及神经退行性疾病等。磷脂酰肌醇（PI）经过PI4Ks磷酸化产生磷脂酰肌醇4-磷酸（PI4P），它在高尔基功能、蛋白质分选以及膜运输等方面也发挥着关键性的作用，其中对外源病原体（如病毒）在宿主内的复制与扩增也起重要作用。因此，有关PI4Ks的抑制剂广谱抗病毒的研究成为当前药物化学研究的热点之一脂质磷脂酰肌醇是无数细胞过程的重要调节因子，包括信号传导、膜运输和胞质分裂。磷脂酰肌醇通过磷脂酰肌醇的肌醇环磷酸化产生。在哺乳动物中，有四种不同的PI4K酶：两种II型酶（PI4KIIα和PI4KIIβ）和两种III型酶（PI4KIIIα和PI4KIIIβ）。
PI4KIIIβ是一种分布在高尔基体以及质膜上的外周膜蛋白，在介导脂质转运和细胞分裂中起关键作用。PI4KIIIβ蛋白由801个氨基酸残基组成，包括一个螺旋结构域和一个脂质激酶结构域以及介导与调节蛋白结合的3个无序区域。PI4KIIIβ的N端主要负责与高尔基体的蛋白（如酰基辅酶A结合结构域蛋白3，ACBD3）发生作用进而募集；其C端包含一个两亲性的脂质堆积传感器基序负责病毒信号传感与转运。多种病毒（包括常见的脊髓灰质炎病毒、柯萨奇病毒以及丙型肝炎病毒等）在宿主细胞复制都需要依赖于病毒复制位点PI4KIIIβ及其催化产物PI4P，因此，PI4KIIIβ也是许多病毒复制的关键因子。一般表现为病毒劫持PI4KIIIβ形成含有PI4P的复制细胞器（ROs），从而诱导病毒蛋白在生物膜上形成复制结构。PI4K IIIβ在人类遗传疾病中也发挥着关键性作用，PI4KIIIβ通过调节骨形态发生蛋白膜II型受体（BMPR2）和信号传导蛋白1/5/9（Smad1/5/9），进而影响靶基因HES相关家族bHLH转录因子与YRPW基序1（hey1）的转录激活，最终影响斑马鱼前庭器官发育。STING是先天免疫反应的关键信号转导因子，cGAS-STING通路的激活，触发外源性DNA，从而调节自发性抗肿瘤、抗DNA病毒等免疫反应。ARMH3是STING激活的关键因子，ARMH3通过募集PI4KIIIβ，从而激活STING的目的。
组蛋白脱乙酰酶（HDACs）是一类表观遗传酶，催化从组蛋白和其他蛋白质的赖氨酸残基中去除乙酰基，从而调节染色质结构和转录活性。HDAC的经典异羟肟酸抑制剂——伏立诺他（SAHA，Vorinostat），其结构包含形成药效团的三个主要元素的序列：帽、连接体和锌结合基（ZBG）。一方面，连接体与ZBG结合，并促进其渗透到HDAC活性位点的疏水性“隧道”中，在其底部发生催化锌离子的螯合作用。另一方面，连接体与帽状结构相关，最常见的是芳基或杂芳基自由基，其额外地与蛋白质底物结合腔相互作用，影响抑制的强度和选择性。最近的蛋白质组学研究揭示了小鼠和人类肝细胞中广泛的乙酰化。HCV感染引起的HDAC活性的上调也有报道。此外，三种HDAC酶（HDAC2、3和5）的多态性已被证明与慢性HCV的持续病毒学反应独立相关。许多观察结果表明，HDAC抑制剂在阻断HCV复制方面具有前景，且近期苯甲异羟肟酸和泛HDAC抑制剂伏立诺他(SAHA)已被报道为潜在的抗HCV药物。
根据已有的文献资料表明，同时抑制PI4KIIIβ与HDAC可高效阻断HCV复制，并通过提高疗效从而限制耐药性，PI4KIIIβ与HDAC的选择性抑制剂可能具有更低的毒性，目前还尚未有文献报道关于PI4KIIIβ/HDAC双靶抑制剂 。
发明内容
本发明的目的是针对现有技术存在的缺陷，提出一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、其制备方法，含抑制剂的药物组合物及应用，提高抑制活性。
本发明首先提供：一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂，为通式I所示的取代苯基噻唑胺类化合物，或其立体异构体、水合物或药学上可接受的盐：其中，R1-R4为苯环上取代基选自氢、氟、氯、溴、碘、羟基、氨基、氰基、C1-C6烷基、卤代C1-C6烷基、羟基C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、羟基C1-C6烷氧基或C1-C6烷氧基C1-C6烷基；
R5和R6选自C1-C6烷基、含一个或多个取代基的C1-C6烷基、C1-C6烷氧基、含一个或多个取代基的C1-C6烷氧基、C1-C6烷基酰基、C1-C6烷基磺酰基、C3-C6杂环基、含一个或多个取代基的C3-C6杂环基。
X选自砜基或羰基；
Y选自C1-C6亚烷基、含一个或多个取代基的C1-C6亚烷基、4-取代苯基、4-取代的苄基或4-取代的苯氧乙基等；Z选自如下结构：。优选的，所述通式I的抑制剂中，与碳相连的氢替换为氢的同位素氘。
进一步优选为，烷基由氘代烷基替代，烷氧基由氘代环氧基替代，苯环由氘代苯环替代，芳环由氘代芳环替代。
优选的，药学上可接受的盐是指把母体化合物中的碱性基团转换成盐的形式；其中，药学上可接受的盐为碱性基团，进一步优选为胺基或氨基的无机或有机酸盐类；由母体化合物中的碱性基团与1-4当量的酸在一个溶剂系统中反应。
优选的，本发明中化合物碱性基团可与酸成盐，所述酸成盐具体为，与无机酸，尤其氢卤酸(如氢氯酸、氢溴酸、氢碘酸)、硝酸、硫酸、磷酸、碳酸等形成的盐；低级烷基磺酸，如甲磺酸，三氟甲磺酸形成的盐；与芳基磺酸，如苯磺酸或对甲苯磺酸形成的盐；与有机酸，如乙酸、富马酸、酒石酸、草酸、柠檬酸、马来酸、苹果酸或琥珀酸形成的盐；与氨基酸，如天冬氨酸或谷氨酸形成的盐。
优选的，本发明的化合物和药学上可接受的盐还包括溶剂化物或水合物的形式。
优选的，本发明的苯基噻唑胺类PI4KIIIβ抑制剂中化合物的结构式包括同分异构形式，如对映异构、非对映异构、几何异构或构象异构，具体为含有不对称中心的R、S构型，双键的(Z)、(E)异构体，(Z)、(E)的构象异构体。
优选的，所述抑制剂为以下其中之一：
（1）N-羟基-3-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
（2）N-羟基-4-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（3）N-羟基-5-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
（4）N-羟基-6-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
（5）N-羟基-7-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
（6）N-羟基-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
（7）N-羟基-4-(2-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰氨基)乙氧基)苯甲酰胺；
（8）N-羟基-4-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（9）N-羟基-4-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（10）N-羟基-4-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（11）N-羟基-4-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（12）N-羟基-4-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（13）N-羟基-4-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
（14）N-羟基-3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
（15）N-羟基-5-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
（16）N-羟基-6-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
（17）N-羟基-4-(((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
（18）N-羟基-7-((2-甲氧基-5-(4-甲基-2-乙酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
（19）N-羟基-5-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
（20）N-羟基-5-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
（21）N-羟基-4-(((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
（22）N-羟基-5-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
（23）N-羟基-7-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
（24）N-羟基-4-(((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
（25）N-羟基-3-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
（26）N-羟基-6-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
（27）N-羟基-7-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
（28）N-羟基-4-(((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
（29）N-(2-氨基-4-氟苯基)-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺)甲基)苯甲酰胺；
（30）N-(7-(羟基氨基)-4-氧代丁基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
（31）N-(7-(羟基氨基)-7-氧代庚基) -5-(2-异丁酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
（32）N-(7-(羟基氨基)-7-氧代庚基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
（33）N-(4-(羟基氨基甲酰基)苄基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺。
上述抑制剂的制法为，根据目标化合物的制备方法之一，以4-甲氧基苯丙酮为原料(1)，原料(1)与氯磺酸在苯环3号位发生取代反应得到中间体(2)；在中间体(2)的基础上通过Hinsberg 反应，引入氨基羧酸甲酯得到中间体(3)；中间体(3)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(4)；硫脲(5)与多种酰氯反应得到N-取代硫脲(6)，与中间体(4)缩合反应得到中间体(7)；中间体(7)与羟胺发生酰胺缩合得到目标化合物(8)。制备路线如下：。
上述抑制剂的制法还包括，根据目标化合物的制备方法，以4-甲氧基苯丙酮为原料(1)，原料(1)与氯磺酸在苯环3号位发生取代反应得到中间体(2)；在中间体(2)的基础上通过Hinsberg反应，引入氨基羧酸甲酯得到中间体(3)；中间体(3)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(4)；硫脲(5)与多种酰氯反应得到N-取代硫脲(6)，与中间体(4)缩合反应得到中间体(7)；中间体(7)与4-氟-1,2-苯二胺发生酰胺缩合得到目标化合物(9)。制备路线如下：。
上述抑制剂的制法还包括，以5-甲酰基-2-甲氧基苯甲酸甲酯为原料(10)，经过两步反应得到中间体(11)；中间体(11)在乙酸中加热回流与铁粉发生还原反应得到中间体(12)；中间体(12)在酸性条件下发生水解反应得到中间体(13)；中间体(13)被二氯亚砜氯化生成中间体(14)；中间体(14)与氨基羧酸甲酯反应得到中间体(15)；中间体(15)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(16)；中间体(16)与N-取代硫脲缩合反应得到中间体(17)；中间体(17)与羟胺发生酰胺缩合得到目标化合物(18)。制备路线如下：。
本发明进一步提供一种药物组合物，包含至少一种药学上可接受的辅料、辅助剂或载体，以及上述的苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂。
本发明再进一步提供苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂或药物组合物在制备用于抑制丙型肝炎病毒生长的药物中的应用，同时用于预防、治疗或辅助治疗由HCV病毒引起的丙型肝炎。
由于PI4KIIIβ靶点的抑制活性不强，抗丙型肝炎病毒作用不足且无文献报道PI4KIIIβ/HDAC双靶抑制剂，PIK-93被选为进一步结构修饰的先导化合物。本发明确定以苯基噻唑胺为基本骨架结构，通过筛选取代基团，实现对PI4KIIIβ和HDAC的高效抑制，进而抑制HCV病毒的生长，同时对细胞毒性较小，从而可潜在地用于临床治疗药物。其有益效果：（1）具有有效抑制PI4KIIIβ的PI3K/Akt/mTOR信号通路的特点，具有高效优异的PI4KIIIβ/HDAC双酶抑制活性；（2）成本低、疗效佳、毒性小，且在合成过程中的中间产物收率高，降低了资源浪费，进而有利于降低成本；（3）有较高抗丙型肝炎病毒的活性，使用剂量小。
具体实施方式
下面结合实施例对本发明的技术方案作进一步说明。
试剂购买于商品供应商如安徽泽升科技有限公司、百灵威科技有限公司、阿拉丁试剂有限公司、北京偶合科技有限公司等，使用时都没有经过进一步纯化，除非其他方面表明。一般的试剂从西陇化工股份有限公司、南京化学试剂股份有限公司、国药集团化学试剂有限公司和青岛海洋化工有限公司等购买得到。实施例中除非其他方面表明所有的温度定为摄氏度。
下面所描述的实施例中色谱柱使用硅胶柱，硅胶（200-300目）购于青岛海洋化工有限公司。核磁共振光谱以Chloroform-d或DMSO-d 6为溶剂（以ppm为单位）)，用TMS（0 ppm）作为参照标准。当出现多重峰的时候，将使用下面的缩写：s（singlet，单峰），d（doublet，双峰），t（triplet ，三重峰），m（multiplet，多重峰），br（broadened ，宽峰），dd（doublet ofdoublets，双双重峰），dt（doublet of triplets，双三重峰）。偶合常数，用赫兹（Hz）表示。
下面所描述的实施例中低分辨率质谱（MS）数据通过配备G1311B四元泵和G1316A柱温箱的Agilent 6120系列LC-MS的G1329B自动采样器和 G4212B检测器应用于分析，ESI源应用于LC-MS光谱仪。
下面描述的实施例为了便于表述，部分原料会以其简称进行描述，这些简称与其全称对照说明如下：DCM为CH2Cl2，即二氯甲烷；Chloroform-d与CDC13为氘代氯仿；PE为石油醚；EtOAc与EA均为乙酸乙酯；MeOH与CH3OH均为甲醇；ClSO3H为氯磺酸；TEA与Et3N为三乙胺；DMSO-d 6为六氘代二甲亚砜；THF为四氢呋喃；NaCl为氯化钠；Na2SO4为硫酸钠；CDI为N,N-羰基二咪唑。
实施例1
N-羟基-3-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺的合成，合成步骤如下：
步骤1：2-甲氧基-5-（2-氧代丙基）苯磺酰氯的合成，结构式：，量取10 mL的ClSO3H (132 mmol，11.0 eq.)加到25 mL的茄形反应瓶中在冰浴下预冷30min，将2.02 g（12.0 mmol）4-甲氧基苯基丙酮缓慢的滴加到ClSO3H中，室温反应大约6 h，通过TLC点板至原料全部消耗完。将反应液缓慢滴加到冰块上淬灭未反应的ClSO3H，再用乙酸乙酯溶液（3x100 mL）萃取上述水溶液，收集有机相，用饱和氯化钠水溶液（50 mL）洗涤有机相，经无水硫酸钠干燥，减压浓缩得到粗品，经硅胶柱层析（PE:EA=4:1-2:1）纯化。黄色固体，收率：60 %。1H NMR (300 MHz, Chloroform-d) δ 7.77 (s, 1H), 7.54 (d, J = 2.3Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 3.77 (s, 4H), 2.26 (s, 5H).
步骤2：3-((2-甲氧基-5-(2-氧代丙基)苯基)磺酰胺基)丙酸甲酯的合成，结构式：，称取5 mmol的2-甲氧基-5-（2-氧代丙基）苯磺酰氯溶于20mL二氯甲烷中，将7.5 mmol的3-氨基丙酸甲酯盐酸盐（1.5 eq.）和1.52 g三乙胺（3.0 eq.）加至反应液中室温搅拌12 h至2-甲氧基-5-（2-氧代丙基）苯磺酰氯全部消耗完。反应结束经浓缩柱层析（PE:EA=1:1）纯化。白色固体，收率：75 %。1H NMR (400 MHz, Chloroform-d)δ 7.52 (dt, J = 2.1, 1.0 Hz, 1H), 7.25 (ddt, J = 8.4, 2.2, 1.1 Hz, 1H), 7.01– 6.93 (m, 2H), 3.82 (s, 3H), 3.78 (t, J = 1.0 Hz, 2H), 3.64 (s, 3H), 3.15(q, J = 6.3 Hz, 2H), 2.75 (t, J = 6.2 Hz, 2H).
步骤3：3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酸甲酯的合成，结构式：，称取1 mmol 3-((2-甲氧基-5-(2-氧代丙基)苯基)磺酰胺基)丙酸甲酯溶于5 mL四氢呋喃溶液中并置于茄形瓶中，在冰浴状态下，缓慢滴加含有1.1 mmol的苯基三甲基三溴化铵的10 mL的四氢呋喃溶液至上述反应液中，滴加结束撤去冰浴于室温反应0.5 h至反应物全部消耗完，经纯化（PE:EA=1:1）得到溴代产物（3-((5-(1-溴乙基)-2-甲氧基苯基)磺酰胺基)丙酸甲酯）。淡黄色油状物，收率：60 %。（1H NMR (300 MHz, Chloroform-d) δ 7.95 – 7.91 (m, 1H), 7.45 – 7.39(m, 1H), 7.14 (d, J = 8.4 Hz, 1H), 7.06 (t, J = 6.7 Hz, 1H), 5.90 (d, J = 0.9Hz, 1H), 3.89 (s, 2H), 3.64 (s, 2H), 3.19 (q, J = 6.3 Hz, 2H), 2.66 (t, J =6.2 Hz, 2H)）。之后，先制备N-特戊酰硫脲，称10 mmol的硫脲溶于30 mL的无水甲苯溶液中并置于100 mL的茄形瓶中，称取15 mmol的特戊酰氯溶于2 mL无水甲苯中并缓慢滴加至反应器中，将反应升温至110 ℃回流反应5 h，反应结束将反应液冷却至室温浓缩反应液，经柱层析（PE:EA=8:1）得到白色固体N-特戊酰硫脲，收率：71 %（1H NMR (400 MHz,Chloroform-d) δ 9.84 (s, 1H), 8.87 (s, 2H), 1.34 (s, 9H)）。称取1 mmol中间体于25 mL的茄形瓶中，加入10 mL丙酮溶液，再将N-特戊酰硫脲（1.0 eq.）加入反应液中，升温至 60℃回流反应1 h，TLC监测直到中间体全部消耗完（DCM:MeOH=25:1），真空浓缩，柱层析纯化。白色固体，收率：60 %。1H NMR (400 MHz, Chloroform-d) δ 8.24 (d, J = 2.2 Hz,1H), 7.56 (dd, J = 7.9, 2.2 Hz, 1H), 7.02 (d, J = 7.9 Hz, 1H), 7.00 (t, J =6.7 Hz, 1H), 3.70 (s, 2H), 3.44 (s, 2H), 3.02 (q, J = 6.3 Hz, 2H), 2.62 (t, J= 6.2 Hz, 2H), 1.14 (s, 7H).
步骤4：N-羟基-3-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺的合成，结构式如下：，首先制备3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酸，称5 mmol的3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酸甲酯溶于10 mL的甲醇四氢呋喃水的混合溶液（MeOH:THF:H2O=2:2:1）中并置于50 mL的茄形瓶中，称取10 mmol的氢氧化锂（2 eq.）缓慢滴加至反应瓶中，室温过夜，反应结束将反应液趁热加入冰盐水中析出大量白色固体，干燥后得3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酸粗品。称取1 mmol 3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酸粗品和1.5 mmol的PyBOP缩合剂（1.5 eq.）于25 mL的反应瓶中，加入6 mL DMF溶液，量取590 µL DIPEA（3.5 eq.）加入反应液中，室温搅拌几分钟后加入0.14 g盐酸羟胺（2.0eq.），室温反应6 h后，TLC监测直到中间体全部消耗完（DCM:MeOH=25:1），真空浓缩，柱层析纯化。白色固体，收率：66 %。1H NMR (300 MHz, DMSO-d 6) δ 11.23 (s, 2H), 10.49 (s,1H), 8.77 (s, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.69 (dd, J = 8.5, 2.4 Hz, 1H),7.33 (d, J = 8.7 Hz, 1H), 3.95 (s, 3H), 3.01 (t, J = 7.4 Hz, 2H), 2.34 (s,3H), 2.15 (t, J = 7.3 Hz, 2H), 1.24 (s, 9H). 13C NMR (101 MHz, DMSO-d 6) δ177.18, 167.27, 156.24, 155.77, 142.43, 134.76, 129.40, 128.44, 124.57,122.82, 114.14, 56.87, 40.58, 40.37, 40.16, 39.96, 39.75, 39.54, 39.33,39.22, 33.04, 27.05, 16.19.
实施例2
N-羟基-4-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：35 %。1H NMR (400 MHz, DMSO-d 6) δ 11.85 (s, 1H), 10.34 (s, 1H), 8.70(s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.6, 2.4 Hz, 1H), 7.43 (t, J= 5.9 Hz, 1H), 7.32 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 2.80 (q, J = 6.7 Hz,2H), 2.34 (s, 3H), 1.95 (t, J = 7.5 Hz, 2H), 1.60 (p, J = 7.4 Hz, 2H), 1.24(s, 9H). 13C NMR (101 MHz, DMSO-d 6) δ 177.18, 169.08, 156.21, 155.79, 142.43,134.63, 129.38, 128.87, 124.51, 122.87, 114.09, 56.79, 42.82, 40.59, 40.38,40.17, 39.97, 39.76, 39.55, 39.34, 39.22, 30.02, 27.05, 25.92, 16.20.
实施例3
N-羟基-5-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为5-氨基戊酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：36%。1H NMR (400 MHz, DMSO-d 6) δ 11.85 (s, 1H), 10.32 (s, 1H), 8.68 (s,1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.6, 2.4 Hz, 1H), 7.40 (t, J =5.9 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 3.94 (s, 3H), 2.81 (q, J = 6.5 Hz,2H), 2.34 (s, 3H), 1.88 (t, J = 7.2 Hz, 2H), 1.52 – 1.31 (m, 4H), 1.24 (s,9H). 13C NMR (101 MHz, DMSO-d 6) δ 177.14, 169.32, 156.17, 155.80, 142.40,134.56, 129.37, 129.02, 124.46, 122.91, 114.06, 56.76, 42.83, 40.59, 40.38,40.17, 39.96, 39.75, 39.54, 39.33, 39.22, 32.25, 29.32, 27.05, 22.73, 16.18.
实施例4
N-羟基-6-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为6-氨基己酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：39 %。1H NMR (300 MHz, DMSO-d 6) δ 11.84 (s, 1H), 10.33 (s, 1H), 8.67(s, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.67 (dd, J = 8.6, 2.4 Hz, 1H), 7.41 –7.27 (m, 2H), 3.94 (s, 3H), 2.80 (q, J = 6.5 Hz, 2H), 2.34 (s, 3H), 1.88 (t,J = 7.3 Hz, 2H), 1.38 (dp, J = 16.2, 7.4 Hz, 5H), 1.24 (s, 9H), 1.22 – 1.13(m, 1H). 13C NMR (101 MHz, DMSO-d 6) δ 177.15, 169.44, 156.17, 155.81, 142.41,134.58, 129.38, 129.03, 124.47, 122.91, 114.04, 56.77, 43.01, 40.59, 40.38,40.17, 39.96, 39.75, 39.54, 39.34, 39.22, 32.63, 29.37, 27.04, 26.11, 25.20,16.16.
实施例5
N-羟基-7-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：38 %。1H NMR (300 MHz, DMSO-d 6) δ 11.83 (s, 1H), 10.32 (s, 1H),8.66 (s, 1H), 7.76 – 7.62 (m, 2H), 7.41 – 7.27 (m, 2H), 3.94 (s, 3H), 2.81(q, J = 6.5 Hz, 2H), 2.34 (s, 3H), 1.89 (t, J = 7.3 Hz, 2H), 1.38 (dt, J =20.6, 6.9 Hz, 3H), 1.24 (s, 9H), 1.22 – 1.09 (m, 5H). 13C NMR (101 MHz, DMSO-d 6) δ 177.17, 169.51, 156.20, 155.81, 142.37, 134.56, 129.37, 129.11, 124.46,122.90, 114.03, 56.76, 43.09, 40.59, 40.38, 40.17, 39.96, 39.75, 39.54,39.33, 39.22, 32.63, 29.48, 28.64, 27.04, 26.20, 25.50, 16.15.
实施例6
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (300 MHz, DMSO-d 6) δ 11.85 (s, 1H), 11.15(s, 1H), 9.00 (s, 1H), 8.04 (t, J = 6.4 Hz, 1H), 7.69 (d, J = 2.4 Hz, 1H),7.58 (t, J = 7.8 Hz, 3H), 7.26 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.7 Hz, 1H),4.14 (d, J = 6.2 Hz, 2H), 3.86 (s, 3H), 2.32 (s, 3H), 1.25 (s, 9H). 13C NMR(101 MHz, DMSO-d 6) δ 178.88, 165.27, 161.15, 157.55, 149.05, 142.53, 131.81,131.55, 130.58, 128.42 - 127.92 (m), 125.94, 114.21, 55.80, 47.71, 39.54,27.57, 19.26.
实施例7
N-羟基-4-(2-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰氨基)乙氧基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-(2-氨基乙氧基)苯甲酸甲酯盐酸盐，其他步骤及操作同实施例1；白色固体，收率：49 %。 1H NMR (400 MHz, DMSO-d 6) δ 11.83 (s,1H), 11.05 (s, 1H), 8.92 - 8.87 (m, 1H), 7.76 (d, J = 2.4 Hz, 1H), 7.71 -7.60 (m, 4H), 7.26 (d, J = 8.7 Hz, 1H), 6.87 - 6.80 (m, 2H), 4.00 (t, J = 5.3Hz, 2H), 3.90 (s, 3H), 3.27 (t, J = 5.7 Hz, 2H), 2.33 (s, 3H), 1.25 (s, 9H).13C NMR (101 MHz, DMSO-d 6) δ 178.88, 164.94, 162.74, 161.15, 157.55, 149.05,131.81, 130.58, 129.30, 128.14, 127.23, 126.16, 125.94, 115.25, 114.21,66.73, 55.80, 43.44, 39.54, 27.57, 19.26.
实施例8
N-羟基-4-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为丙酰氯，其他步骤及操作同实施例1；白色固体，收率：42 %。1H NMR (300 MHz, DMSO-d 6) δ 11.03(d, J = 56.8 Hz, 2H), 9.82 (s, 1H), 8.85 (s, 1H), 7.72 (d, J = 2.3 Hz, 1H),7.66 (dd, J = 8.6, 2.4 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 3.93 (s, 3H), 2.80(t, J = 7.1 Hz, 2H), 2.42 (q, J = 7.5 Hz, 2H), 2.31 (s, 3H), 1.94 (t, J = 7.5Hz, 2H), 1.59 (t, J = 7.3 Hz, 2H), 1.09 (td, J = 7.3, 2.6 Hz, 3H). 13C NMR(101 MHz, DMSO-d 6) δ 173.58, 172.12, 161.10, 157.54, 149.05, 131.81, 130.58,128.01, 127.66, 125.82, 114.21, 55.80, 42.78, 31.54, 28.65, 24.85, 19.26,9.52.
实施例9
N-羟基-4-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为丁酰氯，其他步骤及操作同实施例1；白色固体，收率：44 %。1H NMR (300 MHz, DMSO-d 6) δ 12.09(s, 1H), 10.34 (s, 1H), 8.70 (s, 1H), 7.76 – 7.63 (m, 2H), 7.43 (t, J = 5.7Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 2.80 (q, J = 6.7 Hz, 2H),2.41 (t, J = 7.3 Hz, 2H), 2.33 (s, 3H), 1.95 (t, J = 7.4 Hz, 2H), 1.62 (qd, J= 7.3, 3.2 Hz, 4H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ171.70, 169.09, 155.80, 155.41, 142.50, 134.60, 129.38, 128.86, 124.48,122.73, 114.07, 56.79, 42.81, 40.60, 40.40, 40.19, 39.98, 39.77, 39.56,39.35, 37.24, 30.02, 25.92, 18.68, 16.29, 13.95.
实施例10
N-羟基-4-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为异丁酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (300 MHz, DMSO-d 6) δ 10.96(s, 1H), 10.27 (s, 1H), 9.77 (s, 1H), 8.87 (s, 1H), 7.76 – 7.60 (m, 2H), 7.31(d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 2.76 (dt, J = 25.4, 7.0 Hz, 3H), 2.32 (s,3H), 1.95 (t, J = 7.4 Hz, 2H), 1.59 (q, J = 7.2 Hz, 2H), 1.11 (dd, J = 7.0,3.0 Hz, 6H). 13C NMR (101 MHz, DMSO-d 6) δ 178.34, 172.12, 161.34, 157.54,149.05, 131.81, 130.58, 128.01, 127.66, 125.94, 114.21, 55.80, 42.78, 35.73,31.54, 24.85, 19.24, 19.21.
实施例11
N-羟基-4-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为戊酰氯，其他步骤及操作同实施例1；白色固体，收率：43 %。1H NMR (300 MHz, DMSO-d 6) δ12.12 (s, 1H), 10.34 (s, 1H), 8.70 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.68(dd, J = 8.5, 2.4 Hz, 1H), 7.42 (t, J = 5.9 Hz, 1H), 7.31 (d, J = 8.7 Hz,1H), 3.94 (s, 3H), 2.80 (q, J = 6.7 Hz, 2H), 2.43 (t, J = 7.4 Hz, 2H), 2.33(s, 3H), 1.95 (t, J = 7.4 Hz, 2H), 1.68 – 1.51 (m, 4H), 1.37 – 1.26 (m, 2H),0.89 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ 171.70, 169.09, 155.80,155.41, 142.50, 134.60, 129.38, 128.86, 124.48, 122.73, 114.07, 56.79, 42.81,40.60, 40.40, 40.19, 39.98, 39.77, 39.56, 39.35, 37.24, 30.02, 25.92, 18.68,16.29, 13.95.
实施例12
N-羟基-4-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为异戊酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (400 MHz, DMSO-d 6) δ 12.11 (s, 1H), 10.34 (s, 1H), 8.70 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.68(dd, J = 8.5, 2.4 Hz, 1H), 7.42 (t, J = 6.0 Hz, 1H), 7.31 (d, J = 8.7 Hz,1H), 3.94 (s, 3H), 2.80 (q, J = 6.8 Hz, 2H), 2.32 (d, J = 8.4 Hz, 5H), 2.08(m, J = 6.9 Hz, 1H), 1.95 (t, J = 7.4 Hz, 2H), 1.60 (m, J = 7.2 Hz, 2H), 0.92(d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, DMSO-d 6) δ 173.97, 172.12, 161.50,157.54, 149.05, 131.81, 130.58, 128.01, 127.66, 125.82, 114.21, 55.80, 46.39,42.78, 31.54, 25.22, 24.85, 22.53, 19.26
实施例13
N-羟基-4-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨基丁酸甲酯盐酸盐以及步骤3中的特戊酰氯改为己酰氯，其他步骤及操作同实施例1；白色固体，收率：46 %。1H NMR (300 MHz, DMSO-d 6) δ12.10 (s, 1H), 10.32 (s, 1H), 8.68 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.68(dd, J = 8.6, 2.4 Hz, 1H), 7.40 (t, J = 5.9 Hz, 1H), 7.31 (d, J = 8.6 Hz,1H), 3.94 (s, 3H), 2.80 (q, J = 6.7 Hz, 2H), 2.42 (t, J = 7.4 Hz, 2H), 2.33(s, 3H), 1.97 (d, J = 11.7 Hz, 2H), 1.60 (p, J = 7.2 Hz, 4H), 1.37 – 1.22 (m,J = 5.5 Hz, 4H), 0.87 (t, J = 6.7 Hz, 3H).13C NMR (101 MHz, DMSO-d 6) δ 171.84,169.08, 155.78, 155.42, 142.49, 134.60, 129.38, 128.83, 124.48, 122.72,114.05, 56.77, 42.80, 35.30, 31.18, 30.01, 25.91, 24.88, 22.29, 16.29, 14.29.
实施例14
N-羟基-3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺，结构式如下：，
将实施例1中步骤3中的特戊酰氯改为戊酰氯，其他步骤及操作同实施例1；白色固体，收率：42 %。1H NMR (300 MHz, DMSO-d 6) δ 12.14 (s, 1H), 10.46 (s, 1H), 8.77(s, 1H), 7.76 – 7.65 (m, 2H), 7.45 – 7.28 (m, 2H), 3.94 (s, 3H), 3.00 (q, J =6.8 Hz, 2H), 2.43 (t, J = 7.4 Hz, 2H), 2.33 (s, 3H), 2.14 (t, J = 7.4 Hz,2H), 1.58 (p, J = 7.4 Hz, 2H), 1.30 (m, J = 8.6, 7.9 Hz, 2H), 0.89 (t, J =7.3 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ 173.67, 169.83, 161.18, 157.55,149.05, 131.81, 130.58, 128.10, 127.60, 125.82, 114.21, 55.80, 39.99, 36.01,33.99, 26.86, 21.77, 19.26, 13.82.
实施例15
N-羟基-5-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为5-氨基戊酸甲酯盐酸盐以及步骤3中的特戊酰氯改为戊酰氯，其他步骤及操作同实施例1；白色固体，收率：40 %。1H NMR (400 MHz, DMSO-d 6) δ12.10 (s, 1H), 10.31 (s, 1H), 8.66 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67(dd, J = 8.6, 2.4 Hz, 1H), 7.37 (t, J = 5.9 Hz, 1H), 7.30 (d, J = 8.7 Hz,1H), 3.94 (s, 3H), 2.80 (q, J = 6.5 Hz, 2H), 2.43 (t, J = 7.4 Hz, 2H), 2.32(s, 3H), 1.91 (dt, J = 25.8, 7.3 Hz, 2H), 1.59 (p, J = 7.5 Hz, 2H), 1.52 –1.36 (m, 2H), 1.39 – 1.20 (m, 4H), 0.87 (dt, J = 12.6, 7.3 Hz, 3H). 13C NMR(101 MHz, DMSO) δ 171.85, 169.32, 155.79, 155.42, 142.47, 134.54, 129.37,128.98, 124.43, 122.75, 114.03, 56.76, 42.81, 40.58, 40.37, 40.21, 40.16,39.95, 39.75, 39.54, 39.33, 35.05, 32.42, 32.24, 29.31, 27.72, 27.30, 22.73,22.14, 16.28, 14.12.
实施例16
N-羟基-6-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为6-氨基己酸甲酯盐酸盐以及步骤3中的特戊酰氯改为戊酰氯，其他步骤及操作同实施例1；白色固体，收率：36 %。1H NMR (400 MHz, DMSO-d 6) δ12.12 (s, 1H), 10.32 (s, 1H), 8.66 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67(dd, J = 8.6, 2.4 Hz, 1H), 7.39 – 7.27 (m, 2H), 3.94 (s, 3H), 2.79 (q, J =6.6 Hz, 2H), 2.43 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 1.88 (t, J = 7.4 Hz,2H), 1.58 (p, J = 7.5 Hz, 2H), 1.43 – 1.32 (m, 4H), 1.31 – 1.14 (m, 4H), 0.89(t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ 174.80, 173.67, 161.18,157.54, 149.05, 131.81, 130.58, 128.01, 127.75, 125.82, 114.21, 55.80, 43.53,36.01, 32.22, 29.51, 26.86, 26.07, 24.39, 21.77, 19.26, 13.82.
实施例17
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐以及步骤3中的特戊酰氯改为戊酰氯，其他步骤及操作同实施例1；白色固体，收率：30%。1H NMR (400 MHz, DMSO-d 6)δ 11.98 (s, 1H), 11.14 (s, 1H), 8.95 (s, 1H), 8.02 (s, 1H), 7.69 (d, J = 2.3Hz, 1H), 7.58 (td, J = 8.3, 2.1 Hz, 3H), 7.26 (d, J = 8.1 Hz, 2H), 7.14 (d, J= 8.7 Hz, 1H), 4.14 (s, 2H), 3.86 (s, 3H), 2.43 (t, J = 7.4 Hz, 2H), 2.30 (s,3H), 1.59 (p, J = 7.4 Hz, 2H), 1.38 – 1.24 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H).13C NMR (101 MHz, DMSO-d 6) δ 171.85, 164.26, 155.62, 155.43, 142.46, 141.48,134.57, 131.78, 129.32, 129.09, 127.84, 126.97, 124.28, 122.77, 113.74,56.61, 46.36, 35.05, 27.30, 22.13, 16.20, 14.12.
实施例18
N-羟基-7-((2-甲氧基-5-(4-甲基-2-乙酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐以及步骤3中的特戊酰氯改为乙酰氯，其他步骤及操作同实施例1；白色固体，收率：50 %。1H NMR (400 MHz, Chloroform-d)δ 8.79 (d, J = 2.4 Hz, 1H), 8.17 (dd, J = 8.8, 2.4 Hz, 1H), 7.58 (t, J = 5.5Hz, 1H), 7.28 (s, 0H), 7.12 – 6.97 (m, 1H), 4.07 (s, 3H), 3.68 (s, 3H), 3.47(td, J = 7.1, 5.6 Hz, 2H), 2.53 (s, 3H), 2.33 (t, J = 7.5 Hz, 2H), 1.72 –1.58 (m, 5H), 1.41 (m, J = 3.7 Hz, 4H). 13C NMR (101 MHz, DMSO-d 6) δ 171.75,169.57, 164.96, 156.43, 155.21, 141.95, 132.26, 130.55, 124.76, 124.53,123.51, 113.15, 56.55, 35.32, 31.19, 29.43, 26.65, 24.89, 22.28, 16.29,14.28.
实施例19
N-羟基-5-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为5-氨基戊酸甲酯盐酸盐以及步骤3中的特戊酰氯改为丙酰氯，其他步骤及操作同实施例1；白色固体，收率：44 %。1H NMR (400 MHz, DMSO-d 6) δ 11.95(s, 1H), 10.31 (s, 0H), 8.66 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67 (dd, J =8.6, 2.4 Hz, 1H), 7.37 (t, J = 6.0 Hz, 1H), 7.30 (dd, J = 8.7, 1.0 Hz, 1H),3.94 (d, J = 1.4 Hz, 3H), 2.81 (p, J = 6.3 Hz, 2H), 2.41 (t, J = 7.3 Hz, 2H),2.32 (s, 3H), 2.12 (t, J = 7.2 Hz, 1H), 1.94 – 1.83 (m, 1H), 1.62 (h, J = 7.4Hz, 2H), 1.48 (dt, J = 15.2, 7.7 Hz, 1H), 1.44 (s, 1H), 1.43 – 1.29 (m, 2H),0.90 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ 172.54, 169.33, 155.79,155.48, 142.46, 134.53, 129.35, 128.99, 124.44, 122.72, 114.03, 56.76, 42.81,40.58, 40.37, 40.16, 39.95, 39.75, 39.54, 39.33, 32.24, 29.31, 28.68, 22.73,16.30, 9.63.
实施例20
N-羟基-5-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为5-氨基戊酸甲酯盐酸盐以及步骤3中的特戊酰氯改为丁酰氯，其他步骤及操作同实施例1；白色固体，收率：43 %。1H NMR (400 MHz, DMSO-d 6) δ 11.95(s, 1H), 10.31 (s, 0H), 8.66 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67 (dd, J =8.6, 2.4 Hz, 1H), 7.37 (t, J = 6.0 Hz, 1H), 7.30 (dd, J = 8.7, 1.0 Hz, 1H),3.94 (d, J = 1.4 Hz, 3H), 2.81 (p, J = 6.3 Hz, 2H), 2.41 (t, J = 7.3 Hz, 2H),2.32 (s, 3H), 2.12 (t, J = 7.2 Hz, 1H), 1.94 – 1.83 (m, 1H), 1.62 (h, J = 7.4Hz, 2H), 1.48 (dt, J = 15.2, 7.7 Hz, 1H), 1.44 (s, 1H), 1.43 – 1.29 (m, 2H),0.90 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, DMSO-d 6) δ 174.82, 171.70, 155.79,155.40, 142.47, 134.55, 129.37, 129.02, 128.98, 124.43, 122.75, 114.02,56.76, 42.76, 39.75, 39.54, 39.33, 37.23, 33.67, 29.09, 22.04, 18.68, 16.27,14.02, 13.95.
实施例21
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐以及步骤3中的特戊酰氯改为丁酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (400 MHz,DMSO-d 6) δ 12.09 (s, 1H), 11.14 (s, 1H), 8.98 (s, 1H), 8.02 (t, J = 6.4 Hz,1H), 7.69 (d, J = 2.4 Hz, 1H), 7.59 (ddd, J = 9.9, 7.7, 2.0 Hz, 3H), 7.29 –7.23 (m, 2H), 7.14 (d, J = 8.7 Hz, 1H), 4.14 (d, J = 6.2 Hz, 2H), 3.86 (s,3H), 2.41 (t, J = 7.3 Hz, 2H), 2.31 (s, 3H), 1.63 (h, J = 7.3 Hz, 2H), 0.91(t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO-d 6) δ 171.69, 155.64, 155.42,142.46, 141.50, 134.57, 131.79, 129.33, 129.13, 127.83, 126.99, 124.30,122.78, 113.76, 56.62, 46.36, 37.24, 18.68, 16.21, 13.95.
实施例22
N-羟基-5-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为5-氨基戊酸甲酯盐酸盐以及步骤3中的特戊酰氯改为异丁酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (400 MHz, DMSO-d 6) δ12.08 (s, 1H), 10.31 (s, 1H), 8.66 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67(dd, J = 8.6, 2.4 Hz, 1H), 7.37 (t, J = 5.8 Hz, 1H), 7.31 (d, J = 8.7 Hz,1H), 3.94 (s, 3H), 2.81 (q, J = 6.4 Hz, 2H), 2.73 (p, J = 6.8 Hz, 1H), 2.33(s, 3H), 1.88 (t, J = 7.3 Hz, 2H), 1.52 – 1.40 (m, 2H), 1.36 (q, J = 7.2 Hz,2H), 1.12 (d, J = 6.8 Hz, 6H). 13C NMR (101 MHz, DMSO-d 6) δ 175.68, 169.32,155.81, 155.55, 142.48, 134.56, 129.36, 129.01, 124.43, 122.84, 114.05,56.76, 42.82, 40.58, 40.38, 40.17, 39.96, 39.75, 39.54, 39.33, 34.26, 32.24,29.31, 22.73, 19.55, 16.26.
实施例23
N-羟基-7-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐以及步骤3中的特戊酰氯改为异戊酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (300 MHz, DMSO-d 6)δ 12.11 (s, 1H), 10.33 (s, 1H), 8.67 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67(dd, J = 8.6, 2.4 Hz, 1H), 7.42 – 7.26 (m, 2H), 3.94 (s, 3H), 2.80 (q, J =6.3 Hz, 2H), 2.75 – 2.65 (m, 1H), 2.32 (s, 3H), 1.99 (s, 1H), 1.89 (t, J =7.3 Hz, 2H), 1.39 (dq, J = 21.2, 7.1 Hz, 3H), 1.26 – 1.14 (m, 5H), 1.12 (d, J= 6.9 Hz, 6H). 13C NMR (101 MHz, DMSO-d 6) δ 175.68, 169.51, 155.82, 155.56,142.47, 134.55, 129.36, 129.10, 124.43, 122.83, 114.02, 60.23, 56.75, 43.08,34.26, 32.63, 29.47, 28.63, 26.20, 25.50, 19.55, 16.23.
实施例24
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐以及步骤3中的特戊酰氯改为异戊酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (400 MHz,DMSO-d 6) δ 12.08 (s, 1H), 11.14 (s, 1H), 8.98 (s, 1H), 8.03 (t, J = 6.4 Hz,1H), 7.69 (d, J = 2.4 Hz, 1H), 7.61 (d, J = 1.7 Hz, 1H), 7.62 – 7.53 (m, 2H),7.26 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.7 Hz, 1H), 4.14 (d, J = 5.7 Hz, 2H),3.86 (s, 3H), 2.73 (p, J = 6.8 Hz, 1H), 2.31 (s, 3H), 1.12 (d, J = 6.8 Hz,6H). 13C NMR (101 MHz, DMSO-d 6) δ 175.67, 155.65, 155.57, 142.47, 141.48,134.58, 131.79, 129.33, 129.15, 127.83, 126.98, 124.29, 122.86, 113.77,56.62, 46.38, 34.26, 19.56, 16.18.
实施例25
N-羟基-3-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺，结构式如下：，将实施例1中步骤3中的特戊酰氯改为己酰氯，其他步骤及操作同实施例1；白色固体，收率：46 %。1H NMR (400 MHz,DMSO-d 6) δ 12.08 (s, 1H), 11.14 (s, 1H), 8.98 (s, 1H), 8.03 (t, J = 6.4 Hz,1H), 7.69 (d, J = 2.4 Hz, 1H), 7.61 (d, J = 1.7 Hz, 1H), 7.62 – 7.53 (m, 2H),7.26 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.7 Hz, 1H), 4.14 (d, J = 5.7 Hz, 2H),3.86 (s, 3H), 2.73 (p, J = 6.8 Hz, 1H), 2.31 (s, 3H), 1.12 (d, J = 6.8 Hz,6H). 13C NMR (101 MHz, DMSO-d 6) δ 175.67, 155.65, 155.57, 142.47, 141.48,134.58, 131.79, 129.33, 129.15, 127.83, 126.98, 124.29, 122.86, 113.77,56.62, 46.38, 34.26, 19.56, 16.18.
实施例26
N-羟基-6-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为6-氨基己酸甲酯盐酸盐以及步骤3中的特戊酰氯改为己酰氯，其他步骤及操作同实施例1；白色固体，收率：40 %。1H NMR (400 MHz, DMSO-d 6) δ12.05 (s, 1H), 10.31 (s, 1H), 8.65 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.67(dd, J = 8.6, 2.4 Hz, 1H), 7.38 – 7.27 (m, 2H), 3.94 (s, 3H), 2.80 (p, J =6.2 Hz, 2H), 2.42 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 1.89 (t, J = 7.4 Hz,2H), 1.67 – 1.54 (m, 2H), 1.43 – 1.05 (m, 10H), 0.87 (t, J = 6.9 Hz, 3H). 13CNMR (75 MHz, DMSO-d 6) δ 171.85, 169.44, 155.80, 155.42, 142.46, 134.55,129.38, 128.98, 124.44, 122.75, 114.00, 56.75, 42.99, 35.30, 32.63, 31.18,29.35, 26.11, 25.19, 24.88, 22.29, 16.26, 14.29.
实施例27
N-羟基-7-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐以及步骤3中的特戊酰氯改为己酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (400 MHz, DMSO-d 6) δ 12.21 (s, 1H), 10.30 (s, 1H), 8.64 (s, 1H), 7.98 (s, 1H), 7.94 (d, J =1.8 Hz, 1H), 7.71 (d, J = 2.2 Hz, 2H), 2.89 (t, J = 7.0 Hz, 2H), 2.44 (t, J =7.4 Hz, 2H), 2.37 (s, 3H), 1.89 (t, J = 7.4 Hz, 2H), 1.61 (p, J = 7.3 Hz,2H), 1.45 – 1.32 (m, 4H), 1.32 – 1.08 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H). 13CNMR (101 MHz, DMSO-d 6) δ 172.07, 169.50, 156.29, 144.17, 139.11, 133.51,132.89, 132.22, 129.78, 129.44, 121.80, 42.98, 35.31, 32.62, 31.17, 29.53,28.58, 26.12, 25.47, 24.84, 22.28, 16.54, 14.29.
实施例28
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐以及步骤3中的特戊酰氯改为已酰氯，其他步骤及操作同实施例1；白色固体，收率：45 %。1H NMR (300 MHz,DMSO-d 6) δ 12.08 (s, 1H), 11.19 (s, 1H), 9.02 (s, 1H), 8.86 (t, J = 6.1 Hz,1H), 7.79 – 7.68 (m, 3H), 7.56 (dd, J = 8.6, 2.5 Hz, 1H), 7.40 (d, J = 8.2Hz, 2H), 7.25 (d, J = 8.7 Hz, 1H), 4.55 (d, J = 6.0 Hz, 2H), 3.94 (s, 3H),2.41 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 1.60 (p, J = 7.4 Hz, 2H), 1.36 – 1.18(m, 4H), 0.92 – 0.82 (m, 3H).13C NMR (101 MHz, DMSO-d 6) δ 171.75, 165.32,156.59, 155.23, 143.41, 142.01, 132.59, 131.66, 130.66, 127.38, 127.36,124.81, 124.02, 123.44, 113.21, 56.58, 42.90, 35.31, 31.19, 24.89, 22.29,16.30, 14.30.
实施例29
N-(2-氨基-4-氟苯基)-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺)甲基)苯甲酰胺，结构式如下：，将实施例1中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐，以及步骤4中的盐酸羟胺改为4-氟-1,2,-苯二胺，其他步骤及操作同实施例1；白色固体，收率：28 %。1H NMR (400 MHz, DMSO-d 6) δ 9.45 (s, 1H), 8.14 (d, J = 2.2 Hz, 1H), 7.98– 7.92 (m, 2H), 7.77 (dd, J = 7.9, 2.2 Hz, 1H), 7.67 (dd, J = 8.2, 5.0 Hz,1H), 7.47 – 7.40 (m, 3H), 7.17 (d, J = 7.9 Hz, 1H), 6.86 – 6.75 (m, 2H), 4.84(s, 2H), 4.24 (dt, J = 7.2, 1.0 Hz, 2H), 3.90 (s, 3H), 1.14 (s, 9H). 13C NMR(101 MHz, DMSO-d 6) δ 178.88, 173.88, 161.15, 159.89, 157.87, 157.55, 149.05,142.29, 142.01, 141.95, 132.73, 131.81, 130.58, 128.87, 128.27, 128.20,128.14, 126.22, 126.20, 125.94, 122.86, 122.80, 114.21, 106.69, 106.53,102.71, 102.55, 55.80, 47.71, 39.54, 27.57, 19.26.
实施例30
N-(7-(羟基氨基)-4-氧代丁基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺：
步骤1：2-甲氧基-5-（2-氧代丙基）苯甲酸的合成，结构式如下：，将原料10 mmol 5-甲酰基-2-甲氧基苯甲酸甲酯和丁胺（2.0 eg.）溶解于甲苯中回流反应3h，经减压蒸馏至干燥后溶解于10 mL的乙酸中，向反应液缓慢加入1.14 mL硝基乙烷（1.5eq.），将混合物加热至100 ℃反应3 h。反应结束后，将反应液冷却至室温并将其缓慢倒入40 mL冰水溶液中（全程剧烈搅拌），用乙酸乙酯溶液（2x40 mL）萃取混合物，收集有机相，依次用水（2x40 mL），10%碳酸氢钠溶液（2x30 mL）和盐水洗涤有机相，经无水硫酸镁干燥，柱层析纯化（PE:EA=2:1）得到(Z)-2-甲氧基-5-(2-硝基丙烯-1-基)苯甲酸甲酯，收率：80 %；将100 mmol 的铁粉加入到22 mL 乙酸的反应瓶中，在氮气保护下，将溶有(Z)-2-甲氧基-5-(2-硝基丙烯-1-基)苯甲酸甲酯（8 mmol）的12 mL乙酸溶液缓慢滴加到上述反应器中，回流反应2 h 后，冷却反应液至室温，过滤铁粉，向滤液加入30 mL 水，用乙酸乙酯溶液（3x40mL）萃取混合物，收集有机相，依次用水（2x30 mL），10%碳酸氢钠溶液（2x30 mL）和盐水（30mL）洗涤有机相，经无水硫酸镁干燥，柱层析纯化（PE:EA=1:1）得到2-甲氧基-5-(2-氧代丙基)苯甲酸甲酯，收率：90 %。称取2 mmol 2-甲氧基-5-(2-氧代丙基)苯甲酸甲酯经酸解得到白色固体2-甲氧基-5-(2-氧代丙基)苯甲酸，收率：95%（以1.0 mL 盐酸溶液（1 mol/L和4mL 乙酸的混合溶液）作为酸解液）。1H NMR (400 MHz, DMSO-d 6) δ 12.58 (s, 1H), 7.46(d, J = 2.3 Hz, 1H), 7.30 (dd, J = 8.5, 2.4 Hz, 1H), 7.07 (d, J = 8.6 Hz,1H), 3.80 (s, 3H), 3.75 (s, 2H), 2.13 (s, 3H).
步骤2：4-（5-（2-己酰胺基-4-甲基噻唑-5-基）-2-甲氧基苯甲酰胺基）丁酸甲酯的合成，结构式如下：，将2-甲氧基-5-(2-氧代丙基)苯甲酸（1 mmol）与CDI（1 mmol）溶于10 mL DCM溶液中预反应1 h，之后将1.5 mmol4-氨基丁酸甲酯加入反应液中室温反应。反应结束纯化得到4-（2-甲氧基-5-（2-氧丙基）苯甲酰胺基）丁酸甲酯；后根据实例1中的步骤3，将步骤3中的特戊酰氯改己酰氯，即可得到白色固体4-（5-（2-己酰胺基-4-甲基噻唑-5-基）-2-甲氧基苯甲酰胺基）丁酸甲酯，收率：60%。1H NMR (400 MHz, DMSO-d 6) δ 8.42 (d, J = 2.2 Hz, 1H), 7.80 (t, J = 5.0 Hz,1H), 7.69 (dd, J = 8.0, 2.3 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H), 3.93 (s, 2H),3.64 (s, 2H), 3.39 – 3.32 (m, 2H), 2.47 (s, 2H), 2.42 (t, J = 8.0 Hz, 2H),2.31 (t, J = 8.4 Hz, 2H), 1.88 (tt, J = 8.4, 5.8 Hz, 2H), 1.67 – 1.57 (m,2H), 1.39 – 1.25 (m, 4H), 0.92 – 0.86 (m, 3H).
步骤3：N-(7-(羟基氨基)-4-氧代丁基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺的合成，结构式如下：，根据实例1中的步骤4，首先制备4-（5-（2-己酰胺基-4-甲基噻唑-5-基）-2-甲氧基苯甲酰胺基）丁酸，称5 mmol的4-（5-（2-己酰胺基-4-甲基噻唑-5-基）-2-甲氧基苯甲酰胺基）丁酸甲酯溶于10 mL的甲醇、四氢呋喃、水的混合溶液（MeOH:THF:H2O=2:2:1）中并置于50 mL的茄形瓶中，称取10 mmol的氢氧化锂（2 eq.）缓慢滴加至反应瓶中，室温过夜，反应结束将反应液趁热加入冰盐水中析出大量白色固体，干燥后得4-（5-（2-己酰胺基-4-甲基噻唑-5-基）-2-甲氧基苯甲酰胺基）丁酸粗品。称取1 mmol的粗品和1.5 mmol的PyBOP缩合剂（1.5 eq.）于25 mL的反应瓶中，加入6 mL DMF溶液，量取590 µL DIPEA（3.5 eq.）加入反应液中，室温搅拌几分钟后加入0.14 g盐酸羟胺（2.0 eq.），室温反应4 h后，TLC监测直到中间体全部消耗完（DCM:MeOH=30:1），真空浓缩，柱层析纯化。白色固体，收率：70 %。1H NMR (300 MHz,DMSO-d 6) δ 12.06 (s, 1H), 10.41 (s, 1H), 8.72 (s, 1H), 8.28 (t, J = 5.7 Hz,1H), 7.72 (d, J = 2.5 Hz, 1H), 7.53 (dd, J = 8.6, 2.5 Hz, 1H), 7.21 (d, J =8.7 Hz, 1H), 3.92 (s, 3H), 3.27 (q, J = 6.6 Hz, 2H), 2.41 (t, J = 7.4 Hz,2H), 2.32 (s, 3H), 2.02 (t, J = 7.5 Hz, 2H), 1.74 (p, J = 7.3 Hz, 2H), 1.60(p, J = 7.5 Hz, 2H), 1.27 (td, J = 6.4, 3.3 Hz, 4H), 0.92 – 0.82 (m, 3H). 13CNMR (101 MHz, DMSO-d 6) δ 171.75, 169.32, 165.10, 156.46, 155.19, 141.96,132.34, 130.58, 124.71, 124.38, 123.49, 113.11, 56.53, 35.30, 31.19, 30.43,25.78, 24.89, 22.29, 16.29, 14.30.
实施例31
N-(7-(羟基氨基)-7-氧代庚基) -5-(2-异丁酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺，结构式如下：，将实施例30中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐以及步骤3中的己酰氯改为异戊酰氯，其他步骤及操作同实施例30。白色固体，收率：46 %。1H NMR (400 MHz,DMSO-d 6) δ 11.80 (s, 1H), 10.34 (s, 1H), 8.66 (s, 1H), 8.21 (t, J = 5.7 Hz,1H), 7.71 (d, J = 2.5 Hz, 1H), 7.52 (dd, J = 8.6, 2.5 Hz, 1H), 7.21 (d, J =8.7 Hz, 1H), 3.91 (s, 3H), 3.27 (dt, J = 13.2, 6.8 Hz, 2H), 2.73 (p, J = 6.9Hz, 1H), 2.32 (s, 3H), 2.04 – 1.91 (m, 2H), 1.50 (ddt, J = 9.8, 7.3, 4.6 Hz,4H), 1.29 (dt, J = 9.5, 6.2 Hz, 4H), 1.12 (d, J = 6.9 Hz, 6H). 13C NMR (101MHz, DMSO-d 6) δ 175.58, 169.57, 164.96, 156.43, 155.33, 141.96, 132.28,130.54, 124.74, 124.52, 123.58, 113.15, 56.54, 34.26, 32.71, 29.43, 28.79,26.65, 25.61, 19.91, 19.57, 16.27./>
实施例32
N-(7-(羟基氨基)-7-氧代庚基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺，结构式如下：，将实施例30中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为7-氨基庚酸甲酯盐酸盐，其他步骤及操作同实施例30。白色固体，收率：40 %。1H NMR (300 MHz, DMSO-d 6) δ 12.06 (s, 1H), 10.36(s, 1H), 8.69 (s, 1H), 8.22 (t, J = 5.7 Hz, 1H), 7.70 (d, J = 2.5 Hz, 1H),7.53 (dd, J = 8.6, 2.5 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.33– 3.19 (m, 2H), 2.41 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 1.95 (t, J = 7.3 Hz,2H), 1.49 (d, J = 7.2 Hz, 4H), 1.31 – 1.21 (m, 10H), 0.92 – 0.80 (m, 3H).13CNMR (101 MHz, DMSO-d 6) δ 171.85, 169.51, 155.80, 155.41, 142.46, 134.53,129.36, 129.06, 124.43, 122.75, 114.00, 56.75, 43.07, 35.30, 32.63, 31.18,29.47, 28.64, 26.20, 25.50, 24.88, 22.29, 16.26, 14.30.
实施例33
N-(4-(羟基氨基甲酰基)苄基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺，结构式如下：，将实施例30中步骤2中的片段3-氨基丙酸甲酯盐酸盐改为4-氨甲基苯甲酸甲酯盐酸盐，其他步骤及操作同实施例30。白色固体，收率：51 %。1H NMR (300 MHz, DMSO-d 6) δ 12.08 (s, 1H), 11.19(s, 1H), 9.02 (s, 1H), 8.86 (t, J = 6.1 Hz, 1H), 7.79 – 7.68 (m, 3H), 7.56(dd, J = 8.6, 2.5 Hz, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.25 (d, J = 8.7 Hz,1H), 4.55 (d, J = 6.0 Hz, 2H), 3.94 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H), 2.32(s, 3H), 1.60 (p, J = 7.4 Hz, 2H), 1.36 – 1.18 (m, 4H), 0.92 – 0.82 (m, 3H).13C NMR (101 MHz, DMSO-d 6) δ 171.75, 165.32, 156.59, 155.23, 143.41, 142.01,132.59, 131.66, 130.66, 127.38, 127.36, 124.81, 124.02, 123.44, 113.21,56.58, 42.90, 35.31, 31.19, 24.89, 22.29, 16.30, 14.30.
通过以下实验来说明本发明通式(I)代表的化合物所具有的有益效果和应用。
针对本发明抑制剂进行PI4KIIIβ激酶抑制实验：
使用ADP-Glo Luminescent Kinase Assay法测试，激酶反应用到的试剂如下：HEPES (50 mM) pH 7.5 with NaCl (100 mM), EGTA (1.0 mM), MgCl2 (3.0 mM), DTT(2.0 mM) 及CHAPS (0.03 %)。反应过程中，每10 mL含不同浓度的受试化合物 (0.05 nM-1.0 μM)中加入50 μM PIP2及25 μM ATP。反应体系在室温下孵育1h，然后加入10 μL试剂ADP-Glo终止酶反应。数据收集使用Envision软件，并使用Graphpad Prism 5分析及拟合化合物的IC50值。
表1 实施例化合物的PI4KIIIβ酶抑制活性(IC50, nM)
| 实施例 | PI4KIIIβ | 实施例 | PI4KIIIβ | 实施例 | PI4KIIIβ |
| 实施例1 | 42 | 实施例13 | 3.2 | 实施例26 | 29 |
| 实施例2 | 25 | 实施例15 | 6.1 | 实施例27 | 7.6 |
| 实施例3 | 47 | 实施例17 | 13 | 实施例28 | 24 |
| 实施例4 | 56 | 实施例18 | 75 | 实施例29 | 245 |
| 实施例5 | 64 | 实施例19 | 75 | 实施例30 | 17 |
| 实施例6 | 173 | 实施例20 | 18 | 实施例31 | 39 |
| 实施例7 | 154 | 实施例21 | 42 | 实施例32 | 14 |
| 实施例8 | 57 | 实施例22 | 44 | 实施例33 | 22 |
| 实施例9 | 14 | 实施例23 | 204 | PIK93 | 17 |
| 实施例10 | 7.3 | 实施例24 | 81 | PIK93-10 | 6.8 |
| 实施例11 | 2.3 | 实施例25 | 3.7 |
，如表1所示，本发明化合物对PI4KIIIβ激酶具有纳摩尔水平抑制活性，且部分化合物显著优于阳性对照PIK-93，尤其是实施例11、13、25对PI4KIIIβ激酶的抑制活性优于阳性对照PIK-93。由此说明，本发明部分实施例化合物为高效的PI4KIIIβ抑制剂。
针对本发明抑制剂进行HDAC1激酶抑制实验：
使用BPS公司的HDAC1荧光检测试剂盒(Cat#50051)，采用荧光标记法(Fluorescence assay)，对实施例化合物进行了HDAC1抑制活性测试。实验步骤如下：(1)制备1x分析缓冲液(改良的Tris缓冲液)；(2)化合物的稀释：通过Echo在100 %DMSO中将化合物转移至分析板。DMSO的最终分数为1%；(3)酶溶液的制备：在1x检测缓冲液中制备酶溶液；(4)底物溶液的制备：在1x检测缓冲液中加入胰蛋白酶和Ac-肽底物，制成底物溶液；(5)将15μL酶溶液转移至检测板，或对于低对照转移15μL 1x检测缓冲液。在室温下孵育15 min。向每个孔中加入10 μL底物溶液，开始反应；(6)数据收集使用Envision软件，并使用Graphpad Prism 5分析及拟合化合物的IC50值。
表2 实施例化合物的HDAC1酶抑制活性(IC50, nM)
| 实施例 | HDAC1 | 实施例 | HDAC1 | 实施例 | HDAC1 |
| 实施例1 | 809 | 实施例13 | 16 | 实施例26 | 5.4 |
| 实施例2 | 25 | 实施例15 | 114 | 实施例27 | 77 |
| 实施例3 | 119 | 实施例17 | >1000 | 实施例28 | 478 |
| 实施例4 | 70 | 实施例18 | 58 | 实施例29 | >2000 |
| 实施例5 | 53 | 实施例19 | 131 | 实施例30 | 26 |
| 实施例6 | 902 | 实施例20 | 240 | 实施例31 | 53 |
| 实施例7 | 640 | 实施例21 | 627 | 实施例32 | 218 |
| 实施例8 | 24 | 实施例22 | 136 | 实施例33 | 48 |
| 实施例9 | 20 | 实施例23 | 4.1 | Vorinostat | 17 |
| 实施例10 | 12 | 实施例24 | 462 | Tucidinostat | 122 |
| 实施例11 | 11 | 实施例25 | 463 |
，如表2所示，本发明部分化合物对HDAC1具有纳摩尔水平抑制活性，且部分化合物显著优于阳性对照Vorinostat，尤其是实施例10、11、13、23、26对HDAC1激酶的抑制活性优于阳性对照Vorinostat。由此说明，本发明部分实施例化合物为高效的HDAC抑制剂。
结合表1和表2的实验数据，分析对比可得实施例11对PI4KIIIβ和HDAC1均具有最好的激酶抑制活性，分别为2.3 nM和1 nM，对此针对实施例11进行激酶选择性实验，实验方法上述相同，实施例激酶亚型抑制活性结果如表3、4所示。
表3 实施例11的PI3Ks酶抑制活性(IC50, nM)
| 实施例 | PI4KIIIβ | PI3Kα | PI3Kδ | PI3Kγ | hVPS34 |
| 实施例11 | 2.3 | 542 | 47.8 | 1091 | >5000 |
，
表4 实施例11的HDACS酶抑制活性(IC50, nM)
| 实施例 | HDAC1 | HDAC2 | HDAC3 | HDAC4 | HDAC5 | HDAC6 |
| 实施例11 | 11 | 17 | 20 | >5000 | >5000 | 23 |
| 实施例 | HDAC7 | HDAC8 | HDAC9 | HDAC10 | HDAC11 | |
| 实施例11 | >5000 | >1000 | >5000 | 75 | >5000 |
，结合表3和表4的实验数据，分析可知实施例11对PI4KIIIβ的抑制活性最好IC50值达到2.3 nM，也可抑制PI3Kδ的活性，IC50值为47.8 nM。同时实施例11也是一种广谱的HDAC抑制剂，对HDAC1、2、3、6和10均有较好的抑制活性，IC50值分别为11，17，20，23，75 nM。
针对本发明抑制剂进行抗HCV病毒活性测试实验，实验方法如下：
（1）样品处理：将要测活性的样品，用DMSO溶解后，用0.22 μm
滤膜过滤除菌，原药浓度为20 mg/mL。
（2）细胞培养：取出液氮中冷冻的人肝癌细胞株Huh-7.5.1细胞，浸入37 ℃水浴中，振荡使之尽快融化（1 min内在离心管中吸入细胞悬液，加入培养液5 mL，在1000 rpm强度下离心5 min，弃除上层清液。再加入约3-4 mL培养液，混匀后，接种于25 cm2培养瓶中，放入CO2培养箱中培养，次日换培养液。每三天进行细胞传代，在实验前一天对细胞进行换液并观察细胞，让细胞处在良好状态的指数生长期。
（3）病毒培养：在有指数生长期的Huh-7.5.1细胞培养瓶中加入J6/JFH1病毒液，孵育5-8 h弃除上层清液，换入新鲜培养基，每隔两天对细胞进行换液，6天后弃出培养基，然后加入约15 mL培养基培养至第7天，用3000 rpm/min强度离心10 min，收集澄清培养液，分装保存于-80 ℃。
（4）检测方法：MTT法。取对数生长期的Huh-7.5.1细胞，用0.25 %胰酶消化，然后用1000 rpm/min 强度离心３ min，血球计数板计数，调整细胞浓度为9×104 cells/mL后，铺于96孔板（100 μL/well），在37 ℃ 5 % CO2培养箱中培养。贴壁5 h，加入用DMSO梯度稀释的药物，共8个稀释度，且每个梯度设三个重复孔，同时设置空白对照（只含培养基）、DMSO对照、细胞对照、阳性药物对照、药物颜色对照，使培养基终体积为200 μL/well，将培养板置于37 ℃ 5 % CO2培养箱进行培养。第三天在实验孔加5 mg/mL MTT溶液20 μL，在37 ℃ 5% CO2条件下孵育4小时，弃上层清液，加入100 μL/well的DMSO，振荡溶解10 min后，于酶标仪上测定OD490的值。并以软件GraphPad Prism 5.0计算药物IC50（IC50：半数细胞生长抑制浓度，将细胞生长抑制50 %所需的浓度）的值。（HCV复制抑制率公式＝(OD Control-ODDrug)/(OD Control-OD Blank)×100 %）
表5 部分实施例化合物的抗HCV病毒活性
| 实施例 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | 实施例7 |
| CC50 (μM) | 61.74 | 8.38 | 64.33 | 120.1 | 49.31 | 77.04 | 38.44 |
| IC50 (nM) | - | 18.41 | - | 59.96 | - | 1267 | 6027 |
| SI | - | 455.13 | - | 2003 | - | 60.81 | 6.38 |
| 实施例 | 实施例8 | 实施例9 | 实施例10 | 实施例11 | 实施例12 | 实施例13 | 实施例14 |
| CC50 (μM) | 106.1 | 90.56 | 110.23 | 89.41 | 70.12 | 35.63 | 74.46 |
| IC50 (nM) | 614.4 | - | 31634 | 537 | 3594 | 419.9 | 24530 |
| SI | 172.69 | - | 3.48 | 166.5 | 19.51 | 84.85 | 3.04 |
| 实施例 | 实施例15 | 实施例16 | 实施例30 | 实施例31 | 实施例32 | 实施例33 | PIK93-10 |
| CC50 (μM) | 123.5 | 31.94 | 5.32 | 112.9 | 1.74 | 0.37 | 42.63 |
| IC50 (nM) | - | - | - | 46.41 | - | 188.9 | 529.3 |
| SI | - | - | - | 2432.67 | - | 1.96 | 80.54 |
，其中CC50表示细胞半数中毒浓度，它表示导致细胞发生50 %形态改变的药物浓度。IC50表示半数有效浓度，它表示使病毒感染率下降50 %的药物浓度。SI表示选择性，它等于CC50与IC50的比值，用于评估药物的治疗潜力。SI值越高，说明药物在抗HCV病毒的效力越强。“-”表示10 μM初筛对HCV无抑制效果，或无法拟合IC50值。
从表5可以看出，本发明部分实施例对HCV病毒具有较高水平的增殖抑制活性且细胞毒性较低，其中实施例2对HCV病毒达到18.41 nM。特别地实施例4和31的SI值大于2000，且CC50值大于100 μM，IC50值在60 nM以下，显著优于阳性对照PIK93-10。由此可见，本发明部分实施例化合物可潜在用于抗HCV的临床治疗。
除上述实施外，本发明还可以有其他实施方式。凡采用等同替换或等效变换形成的技术方案，均落在本发明要求的保护范围。
Claims (8)
1.一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂，其特征在于：所述抑制剂为通式I所示的取代苯基噻唑胺类化合物，或其立体异构体、水合物或药学上可接受的盐，，其中R1-R4为苯环上取代基，选自氢、氟、氯、溴、碘、羟基、氨基、氰基、C1-C6烷基、卤代C1-C6烷基、羟基C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、羟基C1-C6烷氧基或C1-C6烷氧基C1-C6烷基；
R5和R6选自C1-C6烷基、含一个或多个取代基的C1-C6烷基、C1-C6烷氧基、含一个或多个取代基的C1-C6烷氧基、C1-C6烷基酰基、C1-C6烷基磺酰基、C3-C6杂环基、含一个或多个取代基的C3-C6杂环基；
X选自砜基或羰基；
Y选自C1-C6亚烷基、含一个或多个取代基的C1-C6亚烷基、4-取代苯基、4-取代的苄基或4-取代的苯氧乙基；
Z选自以下结构，。
2.根据权利要求1所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂，其特征在于：所述通式I中与碳相连的氢替换为氢的同位素氘。
3.根据权利要求1或2所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂，其特征在于：所述抑制剂为以下其中之一，
N-羟基-3-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-5-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
N-羟基-6-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
N-羟基-7-((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
N-羟基-4-(2-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰氨基)乙氧基)苯甲酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-4-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丁酰胺；
N-羟基-3-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
N-羟基-5-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
N-羟基-6-((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
N-羟基-7-((2-甲氧基-5-(4-甲基-2-乙酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
N-羟基-5-((2-甲氧基-5-(4-甲基-2-丙酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
N-羟基-5-((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-丁酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
N-羟基-5-((2-甲氧基-5-(4-甲基-2-异丁酰胺基噻唑-5-基)苯基)磺酰胺基)戊酰胺；
N-羟基-7-((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-异戊酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
N-羟基-3-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)丙酰胺；
N-羟基-6-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)己酰胺；
N-羟基-7-((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)庚酰胺；
N-羟基-4-(((2-甲氧基-5-(4-甲基-2-己酰胺基噻唑-5-基)苯基)磺酰胺基)甲基)苯甲酰胺；
N-(2-氨基-4-氟苯基)-4-(((2-甲氧基-5-(4-甲基-2-特戊酰胺基噻唑-5-基)苯基)磺酰胺)甲基)苯甲酰胺；
N-(7-(羟基氨基)-4-氧代丁基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
N-(7-(羟基氨基)-7-氧代庚基) -5-(2-异丁酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
N-(7-(羟基氨基)-7-氧代庚基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺；
N-(4-(羟基氨基甲酰基)苄基)-5-(2-己酰胺基-4-甲基噻唑-5-基)-2-甲氧基苯甲酰胺。
4.根据权利要求3所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂的制备方法，其特征在于：按照以下步骤制备目标化合物（8），以4-甲氧基苯丙酮为原料(1)，原料(1)与氯磺酸在苯环3号位发生取代反应得到中间体(2)；在中间体(2)的基础上通过Hinsberg 反应，引入氨基羧酸甲酯得到中间体(3)；中间体(3)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(4)；硫脲(5)与酰氯反应得到N-取代硫脲(6)，与中间体(4)缩合反应得到中间体(7)；中间体(7)与羟胺发生酰胺缩合得到目标化合物(8)，制备路线如下，。
5.根据权利要求3所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂的制备方法，其特征在于：按照以下步骤制备目标化合物（9），以4-甲氧基苯丙酮为原料(1)，原料(1)与氯磺酸在苯环3号位发生取代反应得到中间体(2)；在中间体(2)的基础上通过Hinsberg 反应，引入氨基羧酸甲酯得到中间体(3)；中间体(3)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(4)；硫脲(5)与酰氯反应得到N-取代硫脲(6)，与中间体(4)缩合反应得到中间体(7)；中间体(7) 与4-氟-1,2-苯二胺发生酰胺缩合得到目标化合物(9)，制备路线如下，。
6.根据权利要求3所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂的制备方法，其特征在于：按照以下步骤制备目标化合物（18），以5-甲酰基-2-甲氧基苯甲酸甲酯为原料(10)，经过两步反应得到中间体(11)；中间体(11)在乙酸中加热回流与铁粉发生还原反应得到中间体(12)；中间体(12)在酸性条件下发生水解反应得到中间体(13)；中间体(13)被二氯亚砜氯化生成中间体(14)；中间体(14)与氨基羧酸甲酯反应得到中间体(15)；中间体(15)与苯基三甲基三溴化铵发生α-溴代反应得到中间体(16)；中间体(16)与N-取代硫脲缩合反应得到中间体(17)；中间体(17)与羟胺发生酰胺缩合得到目标化合物(18)制备路线如下，。
7.一种药物组合物，其特征在于：所述组合物包含至少一种药学上可接受的辅料、辅助剂或载体，以及权利要求1-3任一项所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂。
8.一种如权利要求1-3任一项所述苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂或如权利要求7所述药物组合物在制备用于抑制丙型肝炎病毒生长的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410660509.2A CN118221610A (zh) | 2024-05-27 | 2024-05-27 | 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410660509.2A CN118221610A (zh) | 2024-05-27 | 2024-05-27 | 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118221610A true CN118221610A (zh) | 2024-06-21 |
Family
ID=91508883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410660509.2A Pending CN118221610A (zh) | 2024-05-27 | 2024-05-27 | 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118221610A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101331125A (zh) * | 2005-12-12 | 2008-12-24 | 健亚生物科技公司 | N-(5-元杂芳香环)-酰胺基抗病毒化合物 |
| WO2013052845A1 (en) * | 2011-10-05 | 2013-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| US20190062323A1 (en) * | 2016-02-26 | 2019-02-28 | The Board Of Trustees Of The Leland Stanford Junior University | PI-Kinase Inhibitors with Anti-Infective Activity |
| CN117534631A (zh) * | 2024-01-09 | 2024-02-09 | 南京市鸿舜医药科技有限公司 | 一种苯基噻唑胺类PI4KIIIβ抑制剂、制法及其药物组合物和应用 |
-
2024
- 2024-05-27 CN CN202410660509.2A patent/CN118221610A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101331125A (zh) * | 2005-12-12 | 2008-12-24 | 健亚生物科技公司 | N-(5-元杂芳香环)-酰胺基抗病毒化合物 |
| WO2013052845A1 (en) * | 2011-10-05 | 2013-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| US20190062323A1 (en) * | 2016-02-26 | 2019-02-28 | The Board Of Trustees Of The Leland Stanford Junior University | PI-Kinase Inhibitors with Anti-Infective Activity |
| CN117534631A (zh) * | 2024-01-09 | 2024-02-09 | 南京市鸿舜医药科技有限公司 | 一种苯基噻唑胺类PI4KIIIβ抑制剂、制法及其药物组合物和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3601230B1 (en) | Synthesis of mcl-1 inhibitor | |
| EP2330894B1 (en) | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors | |
| RU2671847C2 (ru) | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона | |
| Rehman et al. | Synthesis, characterization and biological screening of 5-substituted-1, 3, 4-oxadiazole-2yl-N-(2-methoxy-5-chlorophenyl)-2-sulfanyl acetamide | |
| JPS62201882A (ja) | イソフラボン誘導体 | |
| US20050256154A1 (en) | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | |
| WO2011019393A2 (en) | Class- and isoform-specific hdac inhibitors and uses thereof | |
| CA3091342A1 (en) | Susbstituted aryl and heteroaryl acetamide derivatives and pharmaceutical compositions thereof useful as p300/cbp hat_inhibitors | |
| EP3397640B1 (en) | Xanthine derivative inhibitors of bet proteins | |
| Habib et al. | Biofilm inhibition and DNA binding studies of isoxazole-triazole conjugates in the development of effective anti-bacterial agents | |
| Abdelmonsef et al. | Design, synthetic approach, in silico molecular docking and antibacterial activity of quinazolin-2, 4-dione hybrids bearing bioactive scaffolds | |
| Adki et al. | Synthesis and biological evaluation of pyrazole analogues linked with 1, 2, 3-triazole and 4-thiazolidinone as antimicrobial agents | |
| Andrianov et al. | Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR | |
| JP5571771B2 (ja) | イミダゾリジン−２，４−ジオン誘導体及びそれらの医薬製造のための利用 | |
| CN118221610A (zh) | 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用 | |
| Panigrahi et al. | Ultrasound assisted synthesis, characterization and antimicrobial evaluation of novel oxazolidinone-biphenyl chalcone hybrid derivatives | |
| CN113582864B (zh) | Prmti型甲基转移酶抑制活性化合物及其制备与应用 | |
| JP5530939B2 (ja) | Ｈｄａｃ阻害剤としてのスルホニルピロールの新規製造法 | |
| EP4157844B1 (en) | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer | |
| Prajapat et al. | New benzothiazole-thiazolidinone hybrids containing phthalimidoxy and ethoxyphthalimide: Design, synthesis and pharmacological assay | |
| CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
| US20220298156A1 (en) | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors | |
| Bhatt et al. | Synthesis, characterization and anti-microbial activity of pyrazole capped 2-azitidinone derivatives | |
| CN114573567B (zh) | 一种吲唑环联三氮唑类化合物及其制备方法和应用 | |
| KR100553593B1 (ko) | 히스톤 디아세틸라제 저해활성을 갖는 벤즈히드록시아미드유도체 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |